Bill
S 2392
New Jersey bill adds sickle cell anemia to medical cannabis qualifying conditions, allowing patients physician-approved access to cannabis for pain management.
S 2392 authorizes the use of medical cannabis as a treatment option for patients diagnosed with sickle cell anemia in New Jersey. The bill would add sickle cell disease to the list of qualifying conditions under New Jersey's existing medical cannabis program, allowing eligible patients to obtain and use cannabis products with physician authorization.
Sickle cell anemia causes severe pain crises and chronic pain that can be difficult to manage with conventional medications alone. Adding this condition to the medical cannabis program could provide patients with an alternative or complementary pain management option, though the evidence base for cannabis efficacy in sickle cell treatment remains limited compared to other approved conditions.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
